Christos Papadimitriou - Publications

Affiliations: 
2008 University of Athens, Greece, Zografou, Greece 

110 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Apostolou P, Dellatola V, Papadimitriou C, Kalfakakou D, Fountzilas E, Faliakou E, Fountzilas G, Romanidou O, Konstantopoulou I, Fostira F. Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects. Cancers. 13. PMID 33925588 DOI: 10.3390/cancers13092106  0.301
2020 Fostira F, Papadimitriou M, Papadimitriou C. Current practices on genetic testing in ovarian cancer. Annals of Translational Medicine. 8: 1703. PMID 33490215 DOI: 10.21037/Atm-20-1422  0.388
2020 Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulias V, Mavroudis D, et al. BRCA1 & BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. International Journal of Cancer. PMID 32022259 DOI: 10.1002/Ijc.32903  0.354
2020 Fountzilas E, Kotoula V, Koliou GA, Giannoulatou E, Gogas H, Papadimitriou C, Tikas I, Zhang J, Papadopoulou K, Zagouri F, Christodoulou C, Koutras A, Makatsoris T, Chrisafi S, Linardou H, et al. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget. 11: 1-14. PMID 32002119 DOI: 10.18632/Oncotarget.27338  0.39
2020 Hardy-Bessard A, Moore KN, Mirza MR, Asselain B, Redondo A, Pfisterer J, Pignata S, Provencher DM, Cibula D, Reyners AKL, Bodnar L, Glasspool R, Papadimitriou C, Eitan R, Han SN, et al. ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps6101  0.31
2020 Koumarianou A, Makrantonakis P, Zagouri F, Papadimitriou C, Christopoulou A, Samantas E, Christodoulou C, Psyrri A, Bafaloukos D, Aravantinos G, Papakotoulas P, Baka S, Andreadis C, Alexopoulos A, Bombolaki I, et al. Abstract P2-15-07: Real-world multicenter, prospective study of the effects of nab-paclitaxel on clinical outcomes and quality of life of patients with metastatic breast cancer in Greece. The ‘ABReast’ study Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-15-07  0.46
2019 Fountzilas E, Konstantopoulou I, Vagena A, Apostolou P, Papadimitriou C, Christodoulou C, Tryfonopoulos D, Manousou K, Delimitsou A, Papamentzelopoulou M, Fountzilas G, Yannoukakos D, Fostira F. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Clinical Breast Cancer. PMID 31980407 DOI: 10.1016/J.Clbc.2019.08.003  0.402
2019 Fostira F, Kostantopoulou I, Apostolou P, Papamentzelopoulou MS, Papadimitriou C, Faliakou E, Christodoulou C, Boukovinas I, Razis E, Tryfonopoulos D, Barbounis V, Vagena A, Vlachos IS, Kalfakakou D, Fountzilas G, et al. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. Journal of Medical Genetics. PMID 31300551 DOI: 10.1136/Jmedgenet-2019-106189  0.378
2019 Vagena A, Papamentzelopoulou M, Kalfakakou D, Kollia P, Papadimitriou C, Psyrri A, Apostolou P, Fountzilas G, Konstantopoulou I, Yannoukakos D, Fostira F. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk. Journal of Human Genetics. PMID 31089269 DOI: 10.1038/S10038-019-0612-6  0.391
2019 Lampropoulou DI, Aravantinos G, Katifelis H, Lazaris F, Laschos K, Theodosopoulos T, Papadimitriou C, Gazouli M. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer. Cancer Biomarkers : Section a of Disease Markers. PMID 31045514 DOI: 10.3233/Cbm-182383  0.325
2019 Protopapa M, Kouloulias V, Nikoloudi S, Papadimitriou C, Gogalis G, Zygogianni A. From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. Journal of Oncology. 2019: 3267409. PMID 30853981 DOI: 10.1155/2019/3267409  0.358
2019 Kotsakis A, Ardavanis A, Koumakis G, Samantas E, Psyrri A, Papadimitriou C. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study. Bmc Cancer. 19: 88. PMID 30658600 DOI: 10.1186/S12885-019-5301-5  0.38
2019 Michalaki V, Polydorou A, Theodosopoulos T, Frangulidis G, Dafnios N, Plemmenou MF, Papadimitriou C. Microsatellite instability and mutations in BRAF and KRAS in small bowel adenocarcinoma. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E15037  0.342
2019 Fostira F, Kalfakakou D, Papamentzelopoulou MS, Delimitsou A, Apostolou P, Vagena A, Papadimitriou C, Aravantinos G, Fountzilas G, Yannoukakos D, Kostantopoulou I. Abstract 4170: Combination of germline and tumor testing yields a high rate of loss-of-function variants in non-mucinous epithelial ovarian cancer patients Cancer Research. 79: 4170-4170. DOI: 10.1158/1538-7445.Am2019-4170  0.369
2019 Tabernero J, Prager G, Stintzing S, Lenz HJ, Nygren HP, Papadimitriou C. Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz246.141  0.333
2019 Michalaki V, Kontis I, Koutroulis G, Karvouni E, Papadimitriou C. Early assessment of cardiovascular toxicity of pertuzumab plustrastuzumab plus docetaxel for HER-2 positive metastatic breastcancer (MBC) in pretreated patients with trastuzumab in the neo/adjuvant setting The Breast. 44. DOI: 10.1016/S0960-9776(19)30235-8  0.335
2018 Konstanta I, Fostira F, Apostolou P, Stratikos E, Kalfakakou D, Pampanos A, Kollia P, Papadimitriou C, Konstantopoulou I, Yannoukakos D. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece. Journal of Human Genetics. PMID 30111881 DOI: 10.1038/S10038-018-0498-8  0.344
2018 Papadimitriou M, Mountzios G, Papadimitriou CA. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. Cancer Treatment Reviews. 67: 34-44. PMID 29753961 DOI: 10.1016/j.ctrv.2018.04.010  0.32
2018 Michalaki V, Koutroulis G, Kontis I, Frangulidis G, Dafnios N, Karvouni E, Papadimitriou C. Assesment of cardiac effects of ado-trastuzumab emtansine through strain rate imaging in metastatic breast cancer. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E13007  0.335
2018 Carlsson GU, Guren TK, Haux J, Pfeiffer P, Taflin H, Mavroudis D, Georgoulias V, Papadimitriou C, Kentepozidis N, Boumpas D, Skintemo L, Ganlöv KME, Gustavsson B. ISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy281.115  0.352
2017 Michalaki V, Poydorou A, Vezakis A, Frangulidis G, Theodosopoulos T, Papadimitriou C. Gemcitabine plus capecitabine in elderly patients with advanced pancreatic cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii76. PMID 32136014 DOI: 10.1093/Annonc/Mdx261.210  0.368
2017 Batistatou A, Kotoula V, Bobos M, Kouvatseas G, Zagouri F, Tsolaki E, Gogas H, Koutras A, Pentheroudakis G, Timotheadou E, Pervana S, Goussia A, Petraki K, Sotiropoulou M, Koletsa T, ... ... Papadimitriou C, et al. Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. Clinical Breast Cancer. PMID 28870680 DOI: 10.1016/J.Clbc.2017.07.004  0.407
2017 Zagouri F, Kotoula V, Kouvatseas G, Sotiropoulou M, Koletsa T, Gavressea T, Valavanis C, Trihia H, Bobos M, Lazaridis G, Koutras A, Pentheroudakis G, Skarlos P, Bafaloukos D, Arnogiannaki N, ... ... Papadimitriou C, et al. Protein expression patterns of cell cycle regulators in operable breast cancer. Plos One. 12: e0180489. PMID 28797035 DOI: 10.1371/Journal.Pone.0180489  0.362
2017 Gavressea T, Kalogeras KT, Koliou GA, Zagouri F, Lazaridis G, Gogas H, Tsigaridas K, Koutras A, Petraki K, Markopoulos C, Pazarli E, Aravantinos G, Papadimitriou C, Papakostas P, Koufopoulos N, et al. The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. Anticancer Research. 37: 2947-2957. PMID 28551632 DOI: 10.21873/Anticanres.11648  0.394
2017 Strati TM, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Lazaridis G, Lakis S, Pentheroudakis G, Pectasides D, Pazarli E, Christodoulou C, Razis E, Pavlakis K, Magkou C, Chrisafi S, et al. Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. Anticancer Research. 37: 2323-2334. PMID 28476798 DOI: 10.21873/Anticanres.11570  0.377
2017 Levva S, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Papadopoulou K, Lakis S, Koukoulias K, Karavasilis V, Pentheroudakis G, Balassi E, Zagouri F, Kaklamanos IG, Pectasides D, Razis E, et al. Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. Cancer Genomics & Proteomics. 14: 181-195. PMID 28446533 DOI: 10.21873/Cgp.20030  0.375
2017 Michalaki V, Fragulidis G, Kondis I, Karvouni E, Dafnios N, Kotsiou A, Vassiliou I, Papadimitriou C. Safety and efficacy of eribulin in combination with gemcitabine in patients with advanced triple negative breast cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E12578  0.436
2017 Karanikiotis C, Kesisis G, Xanthakis I, Alexopoulos A, Barbounis V, Panopoulos C, Andreadis C, Papadimitriou C. Rationale and design of the real-world Hellenic disease management patterns with everolimus for women with hormone-receptor-positive, human epidermal growth factor ReceptOR-2 negative advanced breast cancer (The MIRROR) study The Breast. 32. DOI: 10.1016/S0960-9776(17)30234-5  0.309
2016 Kouloulias V, Mosa E, Zygogianni A, Kypraiou E, Georgakopoulos J, Platoni K, Antypas C, Kyrgias G, Tolia M, Papadimitriou C, Psyrri A, Patatoukas G, Dilvoi M, Armpilia C, Theodorou K, et al. A Retrospective Analysis of Toxicity and Efficacy for 2 Hypofractionated Irradiation Schedules Versus a Conventional One for Post-Mastectomy Adjuvant Radiotherapy in Breast Cancer. Breast Care (Basel, Switzerland). 11: 328-332. PMID 27920625 DOI: 10.1159/000449433  0.392
2016 Kotoula V, Lakis S, Vlachos IS, Giannoulatou E, Zagouri F, Alexopoulou Z, Gogas H, Pectasides D, Aravantinos G, Efstratiou I, Pentheroudakis G, Papadopoulou K, Chatzopoulos K, Papakostas P, Sotiropoulou M, ... ... Papadimitriou C, et al. Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. Plos One. 11: e0163138. PMID 27685159 DOI: 10.1371/Journal.Pone.0163138  0.326
2015 Karavasilis V, Papadimitriou C, Gogas H, Kouvatseas G, Pentheroudakis G, Koutras A, Christodoulou C, Bafaloukos D, Samantas E, Pisanidis N, Papakostas P, Aravantinos G, Karanikiotis C, Kosmidis P, Pectasides D, et al. Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. Clinical Breast Cancer. PMID 26791750 DOI: 10.1016/J.Clbc.2015.12.001  0.428
2015 Janni W, Sarosiek T, Karaszewska B, Pikiel J, Staroslawska E, Potemski P, Salat C, Brain E, Caglevic C, Briggs K, Mahood K, DeSilvio M, Marini L, Papadimitriou C. Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer. Breast (Edinburgh, Scotland). PMID 26384789 DOI: 10.1016/J.Breast.2015.08.005  0.409
2014 Kouloulias V, Zygogianni A, Kypraiou E, Georgakopoulos J, Thrapsanioti Z, Beli I, Mosa E, Psyrri A, Antypas C, Armbilia C, Tolia M, Platoni K, Papadimitriou C, Arkadopoulos N, Gennatas C, et al. Adjuvant chemotherapy and acute toxicity in hypofractionated radiotherapy for early breast cancer. World Journal of Clinical Cases. 2: 705-10. PMID 25405195 DOI: 10.12998/Wjcc.V2.I11.705  0.397
2014 Kotoula V, Bobos M, Alexopoulou Z, Papadimitriou C, Papadopoulou K, Charalambous E, Tsolaki E, Xepapadakis G, Nicolaou I, Papaspirou I, Aravantinos G, Christodoulou C, Efstratiou I, Gogas H, Fountzilas G. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17. Plos One. 9: e103707. PMID 25098819 DOI: 10.1371/Journal.Pone.0103707  0.369
2014 Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, Xanthakis I, Christodoulou C, Koutras A, Papandreou CN, Papakostas P, Miliaras S, Markopoulos C, Dimitrakakis C, Korantzopoulos P, et al. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. Bmc Cancer. 14: 515. PMID 25026897 DOI: 10.1186/1471-2407-14-515  0.429
2014 Koletsa T, Stavridi F, Bobos M, Kostopoulos I, Kotoula V, Eleftheraki AG, Konstantopoulou I, Papadimitriou C, Batistatou A, Gogas H, Koutras A, Skarlos DV, Pentheroudakis G, Efstratiou I, Pectasides D, et al. alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. Bmc Clinical Pathology. 14: 28. PMID 24987308 DOI: 10.1186/1472-6890-14-28  0.398
2014 Janni W, Sarosiek T, Karaszewska B, Pikiel J, Staroslawska E, Potemski P, Salat C, Brain E, Caglevic C, Briggs K, Desilvio M, Marini L, Papadimitriou C. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Research and Treatment. 143: 493-505. PMID 24402830 DOI: 10.1007/S10549-013-2828-Z  0.423
2014 Mylona E, Melissaris S, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A, Nakopoulou L. Y-box-binding protein 1 (YB1) in breast carcinomas: Relation to aggressive tumor phenotype and identification of patients at high risk for relapse European Journal of Surgical Oncology. 40: 289-296. PMID 24075827 DOI: 10.1016/J.Ejso.2013.09.008  0.367
2013 Dimitrakakis C, Zagouri F, Tsigginou A, Marinopoulos S, Sergentanis TN, Keramopoulos A, Zografos GC, Ampela K, Mpaltas D, Papadimitriou C, Dimopoulos MA, Antsaklis A. Does pregnancy-associated breast cancer imply a worse prognosis? A matched case-case study. Breast Care (Basel, Switzerland). 8: 203-7. PMID 24415971 DOI: 10.1159/000352093  0.372
2013 Fountzilas G, Kotoula V, Pectasides D, Kouvatseas G, Timotheadou E, Bobos M, Mavropoulou X, Papadimitriou C, Vrettou E, Raptou G, Koutras A, Razis E, Bafaloukos D, Samantas E, Pentheroudakis G, et al. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. Plos One. 8: e69256. PMID 23935969 DOI: 10.1371/Journal.Pone.0069256  0.403
2013 Mylona E, Vamvakaris I, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A, Nakopoulou L. An immunohistochemical evaluation of the proteins Wnt1 and glycogen synthase kinase (GSK)-3β in invasive breast carcinomas. Histopathology. 62: 899-907. PMID 23551536 DOI: 10.1111/His.12095  0.326
2013 Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. Bmc Cancer. 13: 163. PMID 23537287 DOI: 10.1186/1471-2407-13-163  0.425
2013 Stavropoulou AV, Fostira F, Pertesi M, Tsitlaidou M, Voutsinas GE, Triantafyllidou O, Bamias A, Dimopoulos MA, Timotheadou E, Pectasides D, Christodoulou C, Klouvas G, Papadimitriou C, Makatsoris T, Pentheroudakis G, et al. Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. Plos One. 8: e58182. PMID 23536787 DOI: 10.1371/Journal.Pone.0058182  0.354
2013 Mylona E, Tzelepis K, Theohari I, Giannopoulou I, Papadimitriou C, Nakopoulou L. Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype. Histopathology. 62: 472-80. PMID 23163571 DOI: 10.1111/His.12013  0.338
2012 Souka E, Alexiadis E, Theohari I, Giannopoulou I, Papadimitriou C, Nakopoulou L. Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas. Histopathology. 61: 644-51. PMID 22882128 DOI: 10.1111/J.1365-2559.2012.04315.X  0.333
2012 Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies Cancer Treatment Reviews. 38: 890-903. PMID 22465195 DOI: 10.1016/J.Ctrv.2012.02.011  0.389
2012 Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D, Papakostas P, Pentheroudakis G, Gogas H, Skarlos P, Samantas E, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment. 134: 353-62. PMID 22434525 DOI: 10.1007/S10549-012-2021-9  0.399
2012 Magkou C, Giannopoulou I, Theohari I, Fytou A, Rafailidis P, Nomikos A, Papadimitriou C, Nakopoulou L. Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathology. 60: 1125-32. PMID 22320867 DOI: 10.1111/J.1365-2559.2011.04143.X  0.428
2012 Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, et al. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment. 132: 609-19. PMID 22187126 DOI: 10.1007/S10549-011-1913-4  0.397
2012 Janni W, Sarosiek T, Pikiel J, Karaszewska B, Staroslawska E, Salat C, Caglevic C, Potemski P, Brain E, Briggs K, Silvio Md, Sapunar F, Papadimitriou C. Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC) Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-18-21  0.405
2012 Tsoukalas N, Tryfonopoulos D, Lypas G, Papadimitriou C, Pistamalntzian N, Panopoulos C, Demiri S, Koumakis G, Barbounis V, Efremidis A. 135 Preliminary Results of a Medical Unit for Prevention-consultation of Familial and Hereditary Breast Cancer European Journal of Cancer. 48. DOI: 10.1016/S0959-8049(12)70203-4  0.326
2012 Tsoukalas N, Tryfonopoulos D, Lypas G, Papadimitriou C, Pistamalntzian N, Panopoulos C, Demiri S, Koumakis G, Barbounis V, Efremidis A. 134 Clinical and Histological Features of Breast Cancer After in Vitro Fertilization European Journal of Cancer. 48. DOI: 10.1016/S0959-8049(12)70202-2  0.353
2011 Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, et al. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Research. 31: 3007-18. PMID 21868552  0.34
2011 Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A, Dimopoulos MA. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology. 77: 682-7. PMID 21256546 DOI: 10.1016/J.Urology.2010.08.044  0.364
2011 Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, Bafaloukos D, Kosmidis P, Murray S. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treatment Reviews. 37: 221-33. PMID 20817364 DOI: 10.1016/J.Ctrv.2010.07.008  0.316
2011 Eleutherakis-Papaiakovou E, Terpos E, Christoulas D, Migkou M, Kastritis E, Gkotzamanidou M, Nikitas N, Manios E, Dimopoulos MA, Papadimitriou C. Low Circulating Mannan-Binding Leptin Levels Correlate with Increased Number of Febrile Episodes in Myeloma Patients Who Undergo High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplantation and Do Not Receive Antibiotic Prophylaxis Blood. 118: 4457-4457. DOI: 10.1182/Blood.V118.21.4457.4457  0.36
2011 Dafni U, Bobos M, Tsolaki E, Batistatou A, Koletsa F, Televantou D, Gogas H, Linardou H, Pectasides D, Kalogeras K, Galani E, Koutras A, Papadimitriou C, Fountzilas G. PD05-02: Effect of HER2/Topoisomerase II alpha (TOP2A) Gene Status or Protein Expression and Chromosome 17 (CEP17) Polysomy on the Outcome of Breast Cancer Patients Treated with Anthracycline-Containing Dose-Dense Sequential Adjuvant Chemotherapy with or without Paclitaxel – A Pooled Analysis of Two Hellenic Cooperative Oncology Group (HeCOG) Phase III Trials. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd05-02  0.452
2011 Pistamaltzian N, Tzavara C, Papadimitriou C, Gyftaki R, Tryfonopoulos D, Panopoulos C, Tsoukalas N, Koumakis G, Demiri S, Koufopoulos N, Misitzis Y, Apostolikas N, Efremidis A. P4-11-15: Increased Propability of Triple Negative Breast Cancer (TNBC) in Premenopausal Patients after Exogenous Hormonal Intake (EHI). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-11-15  0.396
2011 Janni W, Pikiel J, Sarosiek T, Karaszewska B, Papadimitriou C, Schwedler K, Alavarez GJ, Caruso M, Herve R, Lau, Williams L, Briggs K, Sapunar F. OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot1-02-09  0.44
2011 Dimitrakakis C, Tsigginou A, Zagouri F, Sergentanis T, Marinopoulos S, Papadimitriou C, Dimopoulos A-, Zografos G, Antsaklis A. P154 Diagnosis of breast cancer during pregnancy: A five year experience The Breast. 20. DOI: 10.1016/S0960-9776(11)70097-2  0.348
2011 Fountzilas G, Bobos M, Papadimitriou C, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Skarlos P, Koutras A, Dafni U. 5178 POSTER Response of Immunohistochemically (IHC) Defined Breast Cancer Sub-types to Dose-dense Sequential Adjuvant Chemotherapy. Pooled Analysis of Two Randomized Hellenic Cooperative Oncology Group (HeCOG) Phase III Trials European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)71620-3  0.38
2010 Bakarakos P, Theohari I, Nomikos A, Mylona E, Papadimitriou C, Dimopoulos AM, Nakopoulou L. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology. 56: 876-82. PMID 20636791 DOI: 10.1111/J.1365-2559.2010.03570.X  0.37
2010 Mountzios G, Terpos E, Syrigos K, Papadimitriou C, Papadopoulos G, Bamias A, Mavrikakis M, Dimopoulos MA. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. Translational Research : the Journal of Laboratory and Clinical Medicine. 155: 247-55. PMID 20403580 DOI: 10.1016/J.Trsl.2010.01.002  0.378
2010 Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, Dimopoulos MA, Papadimitriou CA. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstetrics and Gynecology International. 2010: 749579. PMID 20148071 DOI: 10.1155/2010/749579  0.3
2010 Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, Papadimitriou C, Rodolakis A, Vlahos G, Dimopoulos MA. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 116: 1462-8. PMID 20108307 DOI: 10.1002/Cncr.24915  0.371
2010 Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis P, Timotheadou E, Makatsoris T, Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D, et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. Bmc Medicine. 8: 3. PMID 20055981 DOI: 10.1186/1741-7015-8-3  0.417
2010 Souliotis VL, Gkotzamanidou M, Sfikakis PP, Terpos E, Papadimitriou C, Migkou M, Eleutherakis-Papaiakovou E, Nikitas N, Kastritis E, Kyrtopoulos SA, Dimopoulos MA. Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma Blood. 116: 2976-2976. DOI: 10.1182/Blood.V116.21.2976.2976  0.328
2010 Tryfonopoulos D, Christakou H, Rapti V, Kontou N, Panopoulos C, Koumakis G, Demiri S, Papadimitriou C, Missitzis I, Apostolikas N, Efremidis A. Abstract PD09-02: Prognostic Effect of Obesity on Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd09-02  0.376
2010 Pistamaltzian N, Papadimitriou C, Panopoulos C, Koumakis G, Demiri S, Tsoukalas N, Yannoukakos D, Apostolikas N, Panagopoulos E, Efremidis A. Abstract P6-10-06: Metachronous Contralateral Breast Cancer (CBC) Has More Aggressive Biology and Clinical Characteristics Compared to Synchronous Bilateral Breast Cancer (BBC) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P6-10-06  0.436
2010 Papadimitriou C, Kourea H, Papazisis K, Christodoulou C, Res E, Papakostas P, Petraki K, Bafaloukos D, Razis E, Fountzilas G. Abstract P2-09-18: High VEGFR1 and VEGFR3 Protein Expression Is Associated with Improved Response to the Combination of Paclitaxel (P) and Bevacizumab (Bev) Therapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-09-18  0.403
2009 Papadimitriou CA, Kalofonos H, Zagouri F, Papakostas P, Bozas G, Makatsoris T, Dimopoulos MA, Fountzilas G. Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group. Oncology. 77: 212-6. PMID 19729979 DOI: 10.1159/000236021  0.326
2009 Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, Fotineas A, Beli I, Chaldeopoulos D, Kouvaris J. Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules (Basel, Switzerland). 14: 1561-77. PMID 19384285 DOI: 10.3390/Molecules14041561  0.334
2009 Terpos E, Christoulas D, Migkou M, Gavriatopoulou M, Papatheodorou A, Eleutherakis-Papaiakovou E, Manios E, Kastritis E, Papadimitriou C, Dimopoulos MA. Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis. Blood. 114: 3863-3863. DOI: 10.1182/Blood.V114.22.3863.3863  0.331
2009 Eleutherakis-Papaiakovou E, Kostis E, Christoulas D, Migkou M, Gavriatopoulou M, Roussou M, Mparmparoussi D, Matsouka C, Manios E, Efstathiou E, Kastritis E, Terpos E, Dimopoulos MA, Papadimitriou C. Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation. Blood. 114: 3334-3334. DOI: 10.1182/Blood.V114.22.3334.3334  0.344
2009 Eleutherakis-Papaiakovou E, Christoulas D, Migkou M, Gavriatopoulou M, Roussou M, Mparmparoussi D, Matsouka C, Manios E, Efstathiou E, Kastritis E, Terpos E, Dimopoulos MA, Papadimitriou C. The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients. Blood. 114: 2279-2279. DOI: 10.1182/Blood.V114.22.2279.2279  0.363
2009 Papadimitriou C, Kalogeras K, Wirtz R, Briasoulis E, Hennig G, Vourli G, Stropp U, Gogas H, Galani E, Samantas E, Makatsoris T, Fountzilas G. Elevated mRNA expression of herstatin predicts poor outcome in patients with high-risk early breast cancer. A possible molecular predictor of treatment benefit in the context of a Hellenic cooperative oncology group trial. Cancer Research. 69: 6066. DOI: 10.1158/0008-5472.Sabcs-6066  0.373
2008 Mountzios G, Dimopoulos MA, Papadimitriou C. Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. Biomarker Insights. 3: 219-226. PMID 19578506 DOI: 10.4137/Bmi.S485  0.392
2008 Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV, Economopoulos T, Kosmidis PA, Stathopoulos GP, Briasoulis E, Pectasides D, Samantas E, Timotheadou E, Papadimitriou C, et al. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. European Journal of Cancer (Oxford, England : 1990). 44: 2169-77. PMID 18691879 DOI: 10.1016/J.Ejca.2008.06.035  0.422
2008 Kalofonos HP, Bamias A, Koutras A, Papakostas P, Basdanis G, Samantas E, Karina M, Misailidou D, Pisanidis N, Pentheroudakis G, Economopoulos T, Papadimitriou C, Skarlos DV, Pectasides D, Stavropoulos M, et al. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer : A Hellenic Cooperative Oncology Group Study European Journal of Cancer. 44: 1693-1700. PMID 18639450 DOI: 10.1016/J.Ejca.2008.05.025  0.388
2008 Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilas G. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Cancer Investigation. 26: 491-8. PMID 18568771 DOI: 10.1080/07357900701829785  0.328
2007 Milingos S, Protopapas A, Papadimitriou C, Rodolakis A, Kallipolitis G, Skartados N, Markaki S, Dimopoulos MA, Antsaklis A. Laparoscopy in the evaluation of women with unexplained ascites: An invaluable diagnostic tool Journal of Minimally Invasive Gynecology. 14: 43-48. PMID 17218228 DOI: 10.1016/J.Jmig.2006.06.020  0.343
2006 Fountzilas G, Pectasides D, Christodoulou C, Timotheadou E, Economopoulos T, Papakostas P, Papadimitriou C, Gogas H, Efstratiou I, Skarlos D. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Medical Oncology (Northwood, London, England). 23: 479-88. PMID 17303906 DOI: 10.1385/Mo:23:4:479  0.412
2006 Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group Bmc Cancer. 6: 228-228. PMID 16999858 DOI: 10.1186/1471-2407-6-228  0.382
2006 Bozas G, Dimopoulos MA, Kastritis E, Efstathiou E, Koutsoukou V, Rodolakis A, Vlahos G, Voulgaris Z, Papageorgiou T, Gika D, Papadimitriou C, Bamias A. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology. 70: 265-72. PMID 16899981 DOI: 10.1159/000094889  0.355
2006 Kastritis E, Efstathiou E, Gika D, Bozas G, Koutsoukou V, Papadimitriou C, Pissakas G, Dimopoulos MA, Bamias A. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. International Journal of Gynecological Cancer. 16: 994-999. PMID 16803475 DOI: 10.1111/J.1525-1438.2006.00596.X  0.372
2006 Papadimitriou C, Harlaftis E, Steeghs D. The Structure and the Partial Opacity of the Spiral Shocks on the Novalike Cataclysmic Variables Astrophysics and Space Science. 304: 315-316. DOI: 10.1007/S10509-006-9140-X  0.624
2005 Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors Journal of Clinical Oncology. 23: 8580-8587. PMID 16314620 DOI: 10.1200/Jco.2005.02.8670  0.418
2005 Kastritis E, Bamias A, Efstathiou E, Gika D, Bozas G, Zorzou P, Sarris K, Papadimitriou C, Dimopoulos MA. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecologic Oncology. 99: 376-382. PMID 16051322 DOI: 10.1016/J.Ygyno.2005.06.024  0.343
2005 Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, et al. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Research and Treatment. 92: 1-9. PMID 15980985 DOI: 10.1007/S10549-005-0322-Y  0.481
2005 Makatsoris T, Kalofonos HP, Aravantinos G, Papadimitriou C, Kastritis E, Rigatos SK, Xiros N, Petsas T, Economopoulos T, Sakadamis AK, Fountzilas G. A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. International Journal of Gastrointestinal Cancer. 35: 103-109. PMID 15879624 DOI: 10.1385/Ijgc:35:2:103  0.382
2005 Aungwerojwit A, Gänsicke BT, Rodríguez-Gil P, Hagen H-, Harlaftis ET, Papadimitriou C, Lehto H, Araujo-Betancor S, Heber U, Fried RE, Engels D, Katajainen S. HS 0139+0559, HS 0229+8016, HS 0506+7725, and HS 0642+5049 : four new long-period cataclysmic variables Astronomy and Astrophysics. 443: 995-1005. DOI: 10.1051/0004-6361:20042610  0.631
2004 Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study Gynecologic Oncology. 95: 695-700. PMID 15581984 DOI: 10.1016/J.Ygyno.2004.08.018  0.375
2004 Bafaloukos D, Papadimitriou C, Linardou H, Aravantinos G, Papakostas P, Skarlos D, Kosmidis P, Fountzilas G, Gogas H, Kalofonos C, Dimopoulos AM. Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. British Journal of Cancer. 91: 1639-1644. PMID 15494721 DOI: 10.1038/Sj.Bjc.6602148  0.363
2004 Dimopoulou I, Efstathiou E, Samakovli A, Dafni U, Moulopoulos LA, Papadimitriou C, Lyberopoulos P, Kastritis E, Roussos C, Dimopoulos MA. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment Annals of Oncology. 15: 1250-1255. PMID 15277266 DOI: 10.1093/Annonc/Mdh311  0.352
2004 Papadimitriou CA, Fountzilas G, Aravantinos G, Kalofonos C, Moulopoulos LA, Briassoulis E, Gika D, Dimopoulos MA. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecologic Oncology. 92: 152-9. PMID 14751151 DOI: 10.1016/j.ygyno.2003.09.021  0.303
2004 Hakala P, Ramsay G, Wheatley PJ, Harlaftis ET, Papadimitriou C. XMM-Newton observations of the dwarf nova YZ Cnc in quiescence Astronomy and Astrophysics. 420: 273-281. DOI: 10.1051/0004-6361:20035843  0.624
2003 Dimopoulos MA, Hamilos G, Efstathiou E, Siapkaras I, Matsouka C, Gika D, Grigoraki V, Papadimitriou C, Mitsibounas D, Anagnostopoulos N. Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide Leukemia & Lymphoma. 44: 993-996. PMID 12854900 DOI: 10.1080/1042819031000077025  0.376
2001 Fountzilas G, Papadimitriou C, Dafni U, Bafaloukos D, Skarlos D, Moulopoulos LA, Razis E, Kalofonos HP, Aravantinos G, Briassoulis E, Papakostas P, Abela K, Gogas E, Kosmidis P, Pavlidis N, et al. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology. 19: 2232-2239. PMID 11304776 DOI: 10.1200/Jco.2001.19.8.2232  0.412
2001 Razis E, Dimopoulos A, Bafaloukos D, Papadimitriou C, Kalogera-Fountzila A, Kalofonos H, Briassoulis E, Samantas E, Keramopoulos A, Pavlidis N, Kosmidis P, Fountzilas G. Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer. Cancer Investigation. 19: 137-144. PMID 11296618 DOI: 10.1081/Cnv-100000148  0.436
1999 Dimopoulos MA, Bakoyannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, Karayannis A, Varkarakis I, Aravantinos G, Zervas A, Pantazopoulos D, Fountzilas G, Bamias A, Kyriakakis Z, Anagnostopoulos A, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group Annals of Oncology. 10: 1385-1388. PMID 10631471 DOI: 10.1023/A:1008379500436  0.424
1999 Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP, Georgoulias V. Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II Study Journal of Clinical Oncology. 17: 1779-1779. PMID 10561215 DOI: 10.1200/Jco.1999.17.6.1779  0.421
1999 Papadimitris C, Dimopoulos MA, Kostis E, Papadimitriou C, Anagnostopoulos A, Alexopoulos G, Papamichael C, Gika D, Mitsibounas D, Stamatelopoulos S. Outpatient Treatment of Neutropenic Fever with Oral Antibiotics and Granulocyte Colony-Stimulating Factor Oncology. 57: 127-130. PMID 10461059 DOI: 10.1159/000012019  0.319
1999 Georgoulias V, Kouroussis C, Androulakis N, Kakolyris S, Dimopoulos MA, Papadakis E, Bouros D, Apostolopoulou F, Papadimitriou C, Agelidou A, Hatzakis K, Kalbakis K, Kotsakis A, Vardakis N, Vlachonicolis J. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial Journal of Clinical Oncology. 17: 914-920. PMID 10071284 DOI: 10.1200/Jco.1999.17.3.914  0.429
1999 Kosmidis PA, Mylonakis N, Skarlos D, Samantas E, Demopoulos MA, Papadimitriou C, Kalophonos C, Pavlidis N, Papakonstantinou C, Fountzilas G. A multicenter randomized trial of paclitaxel (175 mg/m2) plus carboplatin (6AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6AUC) in advanced non-small cell lung cancer (NSCLC) European Journal of Cancer. 35. DOI: 10.1016/S0959-8049(99)81398-7  0.312
1999 Papadimitriou C, Anagnostopoulos A, Voulgaris Z, Vlahos G, Kioses E, Akrivos T, Dimopoulos M. Paclitaxel, cisplatin and epirubicin (PCE) combination chemotherapy for newly diagnosed patients with advanced epithelial ovarian cancer (AEOC) European Journal of Cancer. 35. DOI: 10.1016/S0959-8049(99)81358-6  0.414
1998 Dimopoulos MA, Deliveliotis C, Moulopoulos LA, Papadimitriou C, Mitropoulos D, Anagnostopoulos A, Athanassiades P, Dimopoulos C. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology. 52: 56-60. PMID 9671871 DOI: 10.1016/S0090-4295(98)00150-2  0.343
1998 Georgoulias V, Androulakis N, Dimopoulos AM, Kourousis C, Kakolyris S, Papadakis E, Apostolopoulou F, Papadimitriou C, Vossos A, Agelidou M, Heras P, Tzannes S, Vlachonicolis J, Mavromanolakis E, Hatzidaki D. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study Annals of Oncology. 9: 331-334. PMID 9602269 DOI: 10.1023/A:1008278103446  0.42
1997 Dimopoulos MA, Kostis E, Anagnostopoulos A, Dalezios M, Papadimitris C, Papadimitriou C. Very Late Relapse of Hodgkin's Disease After 24 Years of Complete Remission Leukemia & Lymphoma. 28: 215-217. PMID 9498723 DOI: 10.3109/10428199709058350  0.33
1997 Papadimitris C, Papadimitriou C, Kokolakis N, Athanassiades P, Dimopoulos MA. Late relapse of nonseminomatous germ cell tumor of the testis : Successful treatment with salvage chemotherapy alone Urology. 49: 469-470. PMID 9123720 DOI: 10.1016/S0090-4295(96)00495-5  0.371
1997 Dimopoulos M, Louras G, Pantazopoulos D, Deliveliotis C, Constantinidis C, Papadimitriou C, Papadimitris C, Kyriakakis Z, Mitropoulos D, Georgoulias V. Docetaxel and cisplatin (DC) combination chemotherapy for metastatic urothelial cancer European Journal of Cancer. 33. DOI: 10.1016/S0959-8049(97)84533-9  0.368
Show low-probability matches.